Find a Doctor
Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
Dr. Shefner has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association.
Dr. Shefner received his PhD in sensory physiology from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.
For more information on Dr. Shefner, please call (602) 406-6262.
- Aetna
- Arizona Foundation
- Beech Street
- Blue Cross Blue Shield
- Cigna
- First Health
- Great West
- Health Choice
- Healthnet
- Humana
- Indian Health Services
- Medicare
- Mercy Care (AHCCCS)
- Phoenix Health Plan
- Scan Healthcare
- Secure Horizon
- Tricare
- United Healthcare
- Fellowship, Brigham and Women’s Hospital and Harvard Medical School, Clinical Neurophysiology, 1988-1990
- NINCDS Postdoctoral Research Fellowship, University of Illinois at Chicago, Sensory Physiology, 1977-1979
- Residency, Harvard-Longwood Neurological Training Program, Neurology, 1984-1988
- Internship, Beth Israel Hospital, Medicine, 1983-1984
- MD, Northwestern University (with distinction), 1983
- PhD, University of Illinois, Psychology, 1976
- MA, University of Illinois, Psychology, 1974
- BS, University of Illinois, Mathematics, 1972
- Founder and Co-Chair, Northeast ALS Clinical Trials Consortium (NEALS)
- American Academy of Neurology
- American Association of Electrodiagnostic Medicine
- American Neurological Association
- Best Doctors in America, Best Doctors, 2011-2020
- America’s Top Doctors, Castle Connolly, 2010-2020
- Sheila Essey Award for ALS Research, ALS Association and American Academy of Neurology, 2014
- Alpha Omega Alpha, 1982
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Date: 02/2022
Authors: Sabrina Paganoni, James D Berry, Melanie Quintana, Eric Macklin, Benjamin R Saville, Michelle A Detry, Marianne Chase, Alexander V Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B Chibnik, Matteo Vestrucci, Merit E Cudkowicz, Shafeeq S. Ladha
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
Date: 09/2021
Authors: James Berry, Benjamin Brooks, Angela Genge, Terry Heiman-Patterson, Stanley Appel, Michael Benatar, Robert Bowser, R. Bowser, Merit Cudkowicz, Clifton Gooch, Jeremy Shefner, Jurjen Westra, Wendy Agnese, Charlotte Merrill, Sally Nelson, Stephen Apple
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
Date: 09/2021
Authors: Carol Milligan, Nazem Atassi, Suma Babu, Richard J. Barohn, James B. Caress, Merit E. Cudkowicz, Armineuza Evora, Gregory A. Hawkins, Marlena Wosiski-Kuhn, Eric A. Macklin, Jeremy M. Shefner, Jeremy Shefner, Zachary Simmons, Robert P. Bowser, R. Bowser, Robert Bowser, Shafeeq S. Ladha, Shafeeq Ladha
Evaluation of amyotrophic lateral sclerosis-induced muscle degeneration using magnetic resonance-based relaxivity contrast imaging (RCI)
Date: 06/2021
Authors: Sudarshan Ragunathan, Laura C. Bell, Natenael Semmineh, Ashley M. Stokes, A. Stokes, Jeremy M. Shefner, Jeremy Shefner, Robert Bowser, R. Bowser, Shafeeq Ladha, Shafeeq S. Ladha, C. Chad Quarles, C. Quarles
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial
Date: 03/2021
Authors: Michael D. Weiss, Eric A. Macklin, Courtney E. McIlduff, Steve Vucic, Brian J. Wainger, Matthew C. Kiernan, Stephen A. Goutman, Namita A. Goyal, Seward B. Rutkove, Shafeeq S. Ladha, I. Hweii Amy Chen, Matthew B. Harms, Thomas H. Brannagan, David Lacomis, Sasha Zivkovic, Maxwell Ma, Leo H. Wang, Zachary Simmons, Michael H. Rivner, Jeremy M. Shefner, Jeremy Shefner, Merit E. Cudkowicz, Nazem Atassi
- English
- (602) 406-6262
- Fax: (602) 406-6261
Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multicenter clinical trials, as well as a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
Dr. Shefner has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association.
Dr. Shefner received his PhD in sensory physiology from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.
For more information on Dr. Shefner, please call (602) 406-6262.
- (602) 406-6262
- Fax: (602) 406-6261
- Aetna
- Arizona Foundation
- Beech Street
- Blue Cross Blue Shield
- Cigna
- First Health
- Great West
- Health Choice
- Healthnet
- Humana
- Indian Health Services
- Medicare
- Mercy Care (AHCCCS)
- Phoenix Health Plan
- Scan Healthcare
- Secure Horizon
- Tricare
- United Healthcare
- Fellowship, Brigham and Women’s Hospital and Harvard Medical School, Clinical Neurophysiology, 1988-1990
- NINCDS Postdoctoral Research Fellowship, University of Illinois at Chicago, Sensory Physiology, 1977-1979
- Residency, Harvard-Longwood Neurological Training Program, Neurology, 1984-1988
- Internship, Beth Israel Hospital, Medicine, 1983-1984
- MD, Northwestern University (with distinction), 1983
- PhD, University of Illinois, Psychology, 1976
- MA, University of Illinois, Psychology, 1974
- BS, University of Illinois, Mathematics, 1972
- Founder and Co-Chair, Northeast ALS Clinical Trials Consortium (NEALS)
- American Academy of Neurology
- American Association of Electrodiagnostic Medicine
- American Neurological Association
- Best Doctors in America, Best Doctors, 2011-2020
- America’s Top Doctors, Castle Connolly, 2010-2020
- Sheila Essey Award for ALS Research, ALS Association and American Academy of Neurology, 2014
- Alpha Omega Alpha, 1982
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Date: 02/2022
Authors: Sabrina Paganoni, James D Berry, Melanie Quintana, Eric Macklin, Benjamin R Saville, Michelle A Detry, Marianne Chase, Alexander V Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B Chibnik, Matteo Vestrucci, Merit E Cudkowicz, Shafeeq S. Ladha
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
Date: 09/2021
Authors: James Berry, Benjamin Brooks, Angela Genge, Terry Heiman-Patterson, Stanley Appel, Michael Benatar, Robert Bowser, R. Bowser, Merit Cudkowicz, Clifton Gooch, Jeremy Shefner, Jurjen Westra, Wendy Agnese, Charlotte Merrill, Sally Nelson, Stephen Apple
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
Date: 09/2021
Authors: Carol Milligan, Nazem Atassi, Suma Babu, Richard J. Barohn, James B. Caress, Merit E. Cudkowicz, Armineuza Evora, Gregory A. Hawkins, Marlena Wosiski-Kuhn, Eric A. Macklin, Jeremy M. Shefner, Jeremy Shefner, Zachary Simmons, Robert P. Bowser, R. Bowser, Robert Bowser, Shafeeq S. Ladha, Shafeeq Ladha
Evaluation of amyotrophic lateral sclerosis-induced muscle degeneration using magnetic resonance-based relaxivity contrast imaging (RCI)
Date: 06/2021
Authors: Sudarshan Ragunathan, Laura C. Bell, Natenael Semmineh, Ashley M. Stokes, A. Stokes, Jeremy M. Shefner, Jeremy Shefner, Robert Bowser, R. Bowser, Shafeeq Ladha, Shafeeq S. Ladha, C. Chad Quarles, C. Quarles
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial
Date: 03/2021
Authors: Michael D. Weiss, Eric A. Macklin, Courtney E. McIlduff, Steve Vucic, Brian J. Wainger, Matthew C. Kiernan, Stephen A. Goutman, Namita A. Goyal, Seward B. Rutkove, Shafeeq S. Ladha, I. Hweii Amy Chen, Matthew B. Harms, Thomas H. Brannagan, David Lacomis, Sasha Zivkovic, Maxwell Ma, Leo H. Wang, Zachary Simmons, Michael H. Rivner, Jeremy M. Shefner, Jeremy Shefner, Merit E. Cudkowicz, Nazem Atassi
- English